Details of the Drug

General Information of Drug (ID: DM0FB1J)

Drug Name

Sertraline

Synonyms

Lustral; SRE; Sertralina; Sertralinum; Sertralina [Spanish]; Sertraline [Zoloft]; Sertralinum [Latin]; CP 51974; Cp 51974; Apo-Sertraline; Lustral (TN); Sertraline (INN); Sertraline (Zoloft); Sertraline [INN:BAN]; Zoloft (TN); (+)-Sertraline; (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine; (1S-cis)-1,2,3,4-Tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-1-naphthalenamine; (1S-cis)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine

Indication

Disease Entry	ICD 11	Status	REF
Depression	6A70-6A7Z	Approved	[1], [2]

Therapeutic Class

Antidepressants

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

306.2

Topological Polar Surface Area (xlogp)

4.8

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 20-55 mcg/L [3]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 4.5-8.4 h [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Clearance: The clearance of drug is 1.09 +/- 0.38 L/h/kg [3]
Elimination: The majority of drug is excreted after extensive metabolism, and only 12 - 14% of drug is excreted in unchanged form [5]
Half-life: The concentration or amount of drug in body reduced by one-half in 26 hours [3]
Metabolism: The drug is metabolized via the liver [3]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 9.33 micromolar/kg/day [6]
Vd: The volume of distribution (Vd) of drug is 20 L/kg [5]
Water Solubility: The ability of drug to dissolve in water is measured as 3.8 mg/mL [4]

Chemical Identifiers

Formula: C17H17Cl2N
IUPAC Name: (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine
Canonical SMILES: CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl
InChI: InChI=1S/C17H17Cl2N/c1-20-17-9-7-12(13-4-2-3-5-14(13)17)11-6-8-15(18)16(19)10-11/h2-6,8,10,12,17,20H,7,9H2,1H3/t12-,17-/m0/s1
InChIKey: VGKDLMBJGBXTGI-SJCJKPOMSA-N

Cross-matching ID

PubChem CID: 68617
ChEBI ID: CHEBI:9123
CAS Number: 79617-96-2
DrugBank ID: DB01104
TTD ID: D0K0TC
VARIDT ID: DR00440
INTEDE ID: DR1477
ACDINA ID: D00620

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Serotonin transporter (SERT)	TT3ROYC	SC6A4_HUMAN	Inhibitor	[7], [8]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[10]
Cytochrome P450 2E1 (CYP2E1)	DEVDYN7	CP2E1_HUMAN	Substrate	[11]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[12]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[13]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[14]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[15]
Cytochrome P450 2B6 (CYP2B6)_{Main DME}	DEPKLMQ	CP2B6_HUMAN	Substrate	[14]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Depression

ICD Disease Classification

6A70-6A7Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Serotonin transporter (SERT)	DTT	SLC6A4	8.76E-01	7.18E-05	6.19E-04
P-glycoprotein 1 (ABCB1)	DTP	P-GP	6.54E-01	1.95E-01	4.04E-01
Cytochrome P450 2E1 (CYP2E1)	DME	CYP2E1	9.45E-02	-1.86E-01	-9.83E-01
Cytochrome P450 2B6 (CYP2B6)	DME	CYP2B6	4.32E-01	4.39E-02	4.30E-01
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	8.46E-01	-6.63E-03	-4.49E-02
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	9.62E-01	2.57E-02	1.10E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	8.70E-01	2.98E-02	1.22E-01
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	2.35E-01	2.78E-02	2.09E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.76E-01	1.26E-01	8.27E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Sertraline

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Vilazodone	DM4LECQ	Major	Additive serotonergic effects by the combination of Sertraline and Vilazodone.	Depression [6A70-6A7Z]	[87]
Nefazodone	DM4ZS8M	Major	Additive serotonergic effects by the combination of Sertraline and Nefazodone.	Depression [6A70-6A7Z]	[87]
Vortioxetine	DM6F1PU	Major	Additive serotonergic effects by the combination of Sertraline and Vortioxetine.	Depression [6A70-6A7Z]	[87]
Isocarboxazid	DMAF1NB	Major	Additive serotonergic effects by the combination of Sertraline and Isocarboxazid.	Depression [6A70-6A7Z]	[88]
Milnacipran	DMBFE74	Major	Additive serotonergic effects by the combination of Sertraline and Milnacipran.	Depression [6A70-6A7Z]	[87]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Sertraline and Escitalopram.	Depression [6A70-6A7Z]	[89]
Desvenlafaxine	DMHD4PE	Major	Additive serotonergic effects by the combination of Sertraline and Desvenlafaxine.	Depression [6A70-6A7Z]	[87]
OPC-34712	DMHG57U	Major	Decreased metabolism of Sertraline caused by OPC-34712 mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[90]
-----------


⏷ Show the Full List of 8 DDI Information of This Drug

Coadministration of a Drug Treating the Disease Different from Sertraline (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Insulin-glulisine	DMQI0FU	Moderate	Increased risk of hypoglycemia by the combination of Sertraline and Insulin-glulisine.	Acute diabete complication [5A2Y]	[91]
Insulin-aspart	DMX7V28	Moderate	Increased risk of hypoglycemia by the combination of Sertraline and Insulin-aspart.	Acute diabete complication [5A2Y]	[92]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Sertraline and Ivosidenib.	Acute myeloid leukaemia [2A60]	[93]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and Idarubicin.	Acute myeloid leukaemia [2A60]	[94]
Arn-509	DMT81LZ	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and Arn-509.	Acute myeloid leukaemia [2A60]	[95]
Oliceridine	DM6MDCF	Moderate	Additive serotonergic effects by the combination of Sertraline and Oliceridine.	Acute pain [MG31]	[96]
Inotersen	DMJ93CT	Moderate	Increased risk of bleeding by the combination of Sertraline and Inotersen.	Amyloidosis [5D00]	[97]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Sertraline and Ivabradine.	Angina pectoris [BA40]	[95]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Sertraline and Bepridil.	Angina pectoris [BA40]	[94]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Sertraline and Dronedarone.	Angina pectoris [BA40]	[94]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Sertraline and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[98]
Cilostazol	DMZMSCT	Moderate	Increased risk of bleeding by the combination of Sertraline and Cilostazol.	Arterial occlusive disease [BD40]	[97]
Posaconazole	DMUL5EW	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and Posaconazole.	Aspergillosis [1F20]	[94]
Pirbuterol	DMI5678	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and Pirbuterol.	Asthma [CA23]	[99]
Ofloxacin	DM0VQN3	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[100]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Sertraline caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[101]
Clarithromycin	DM4M1SG	Moderate	Decreased metabolism of Sertraline caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[102]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Sertraline and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[100]
Gemifloxacin	DMHT34O	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[100]
Levofloxacin	DMS60RB	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[100]
Retigabine	DMGNYIH	Moderate	Antagonize the effect of Sertraline when combined with Retigabine.	Behcet disease [4A62]	[103]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and Eribulin.	Breast cancer [2C60-2C6Y]	[94]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and Lapatinib.	Breast cancer [2C60-2C6Y]	[94]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Sertraline caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[104]
Trastuzumab Emtansine	DMU1LXS	Moderate	Increased risk of bleeding by the combination of Sertraline and Trastuzumab Emtansine.	Breast cancer [2C60-2C6Y]	[105]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[106]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Sertraline and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[99]
Vilanterol	DMF5EK1	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[107]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Sertraline and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[99]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Sertraline and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[99]
Levetiracetam	DMTGDN8	Moderate	Antagonize the effect of Sertraline when combined with Levetiracetam.	Chronic pain [MG30]	[103]
Levomilnacipran	DMV26S8	Major	Additive serotonergic effects by the combination of Sertraline and Levomilnacipran.	Chronic pain [MG30]	[87]
Anisindione	DM2C48U	Moderate	Increased risk of bleeding by the combination of Sertraline and Anisindione.	Coagulation defect [3B10]	[97]
Regorafenib	DMHSY1I	Moderate	Increased risk of bleeding by the combination of Sertraline and Regorafenib.	Colorectal cancer [2B91]	[97]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and Halothane.	Corneal disease [9A76-9A78]	[94]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and Sevoflurane.	Corneal disease [9A76-9A78]	[94]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and Probucol.	Coronary atherosclerosis [BA80]	[94]
Ardeparin	DMYRX8B	Moderate	Increased risk of bleeding by the combination of Sertraline and Ardeparin.	Coronary thrombosis [BA43]	[97]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and Osilodrostat.	Cushing syndrome [5A70]	[95]
Lumacaftor	DMCLWDJ	Moderate	Increased metabolism of Sertraline caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[108]
Danaparoid	DM6CLBN	Moderate	Increased risk of bleeding by the combination of Sertraline and Danaparoid.	Deep vein thrombosis [BD71]	[97]
Rivaroxaban	DMQMBZ1	Moderate	Increased risk of bleeding by the combination of Sertraline and Rivaroxaban.	Deep vein thrombosis [BD71]	[97]
5-hydroxy-L-tryptophan	DMDWZGJ	Major	Additive serotonergic effects by the combination of Sertraline and 5-hydroxy-L-tryptophan.	Discovery agent [N.A.]	[109]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[94]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and Deutetrabenazine.	Dystonic disorder [8A02]	[110]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and Ingrezza.	Dystonic disorder [8A02]	[111]
Methsuximide	DM6L5VO	Moderate	Antagonize the effect of Sertraline when combined with Methsuximide.	Epilepsy/seizure [8A61-8A6Z]	[103]
Phenacemide	DMOHS9P	Moderate	Antagonize the effect of Sertraline when combined with Phenacemide.	Epilepsy/seizure [8A61-8A6Z]	[103]
Fosphenytoin	DMOX3LB	Moderate	Decreased metabolism of Sertraline caused by Fosphenytoin mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[112]
Brivaracetam	DMSEPK8	Moderate	Antagonize the effect of Sertraline when combined with Brivaracetam.	Epilepsy/seizure [8A61-8A6Z]	[103]
Lacosamide	DMVM6QR	Moderate	Antagonize the effect of Sertraline when combined with Lacosamide.	Epilepsy/seizure [8A61-8A6Z]	[103]
Rufinamide	DMWE60C	Moderate	Antagonize the effect of Sertraline when combined with Rufinamide.	Epilepsy/seizure [8A61-8A6Z]	[103]
Phenobarbital	DMXZOCG	Moderate	Increased risk of lowers seizure threshold by the combination of Sertraline and Phenobarbital.	Epilepsy/seizure [8A61-8A6Z]	[95]
Eslicarbazepine	DMZREFQ	Moderate	Increased risk of hyponatremia by the combination of Sertraline and Eslicarbazepine.	Epilepsy/seizure [8A61-8A6Z]	[103]
Tazemetostat	DMWP1BH	Moderate	Increased risk of bleeding by the combination of Sertraline and Tazemetostat.	Follicular lymphoma [2A80]	[97]
Solifenacin	DMG592Q	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and Solifenacin.	Functional bladder disorder [GC50]	[94]
Itraconazole	DMCR1MV	Moderate	Decreased metabolism of Sertraline caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[113]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[94]
Avapritinib	DMK2GZX	Moderate	Increased risk of bleeding by the combination of Sertraline and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[97]
Carvedilol	DMHTEAO	Moderate	Decreased metabolism of Sertraline caused by Carvedilol mediated inhibition of CYP450 enzyme.	Heart failure [BD10-BD1Z]	[114]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Sertraline caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[115]
Procarbazine	DMIK367	Major	Additive serotonergic effects by the combination of Sertraline and Procarbazine.	Hodgkin lymphoma [2B30]	[88]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[116]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Sertraline caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[117]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[94]
Nebivolol	DM7F1PA	Moderate	Decreased metabolism of Sertraline caused by Nebivolol mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[114]
Pirfenidone	DM6VZFQ	Moderate	Decreased metabolism of Sertraline caused by Pirfenidone mediated inhibition of CYP450 enzyme.	Idiopathic interstitial pneumonitis [CB03]	[95]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Sertraline and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[94]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Sertraline and Phenolphthalein.	Irritable bowel syndrome [DD91]	[94]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Sertraline caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[95]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Sertraline and Crizotinib.	Lung cancer [2C25]	[118]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Sertraline and Ceritinib.	Lung cancer [2C25]	[94]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Sertraline caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[112]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Sertraline and Osimertinib.	Lung cancer [2C25]	[119]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Sertraline and Selpercatinib.	Lung cancer [2C25]	[95]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Sertraline and Lumefantrine.	Malaria [1F40-1F45]	[112]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Sertraline and Halofantrine.	Malaria [1F40-1F45]	[120]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Sertraline and Hydroxychloroquine.	Malaria [1F40-1F45]	[121]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[95]
Arsenic trioxide	DM61TA4	Major	Increased risk of ventricular arrhythmias by the combination of Sertraline and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[122]
Acalabrutinib	DM7GCVW	Moderate	Increased risk of bleeding by the combination of Sertraline and Acalabrutinib.	Mature B-cell lymphoma [2A85]	[97]
Ibrutinib	DMHZCPO	Moderate	Increased risk of bleeding by the combination of Sertraline and Ibrutinib.	Mature B-cell lymphoma [2A85]	[97]
Ponatinib	DMYGJQO	Moderate	Increased risk of bleeding by the combination of Sertraline and Ponatinib.	Mature B-cell lymphoma [2A85]	[97]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Sertraline and Vemurafenib.	Melanoma [2C30]	[94]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and LGX818.	Melanoma [2C30]	[123]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Sertraline caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[95]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Sertraline and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[124]
Exjade	DMHPRWG	Moderate	Increased risk of bleeding by the combination of Sertraline and Exjade.	Mineral absorption/transport disorder [5C64]	[97]
Flibanserin	DM70DTN	Moderate	Decreased metabolism of Sertraline caused by Flibanserin mediated inhibition of CYP450 enzyme.	Mood disorder [6A60-6E23]	[125]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Sertraline and Panobinostat.	Multiple myeloma [2A83]	[126]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Sertraline and Siponimod.	Multiple sclerosis [8A40]	[112]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Sertraline and Fingolimod.	Multiple sclerosis [8A40]	[94]
Ozanimod	DMT6AM2	Moderate	Additive serotonergic effects by the combination of Sertraline and Ozanimod.	Multiple sclerosis [8A40]	[127]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and Romidepsin.	Mycosis fungoides [2B01]	[94]
Fedratinib	DM4ZBK6	Moderate	Increased risk of bleeding by the combination of Sertraline and Fedratinib.	Myeloproliferative neoplasm [2A20]	[105]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Sertraline and Nilotinib.	Myeloproliferative neoplasm [2A20]	[94]
Ruxolitinib	DM7Q98D	Moderate	Increased risk of bleeding by the combination of Sertraline and Ruxolitinib.	Myeloproliferative neoplasm [2A20]	[97]
Dasatinib	DMJV2EK	Moderate	Increased risk of bleeding by the combination of Sertraline and Dasatinib.	Myeloproliferative neoplasm [2A20]	[97]
Prasugrel	DM7MT6E	Moderate	Increased risk of bleeding by the combination of Sertraline and Prasugrel.	Myocardial infarction [BA41-BA43]	[97]
Vorapaxar	DMA16BR	Moderate	Increased risk of bleeding by the combination of Sertraline and Vorapaxar.	Myocardial infarction [BA41-BA43]	[97]
E-2007	DMJDYNQ	Moderate	Antagonize the effect of Sertraline when combined with E-2007.	Neuropathy [8C0Z]	[103]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and Entrectinib.	Non-small cell lung cancer [2C25]	[112]
Sibutramine	DMFJTDI	Major	Additive serotonergic effects by the combination of Sertraline and Sibutramine.	Obesity [5B80-5B81]	[128]
Lorcaserin	DMG6OYJ	Major	Additive serotonergic effects by the combination of Sertraline and Lorcaserin.	Obesity [5B80-5B81]	[129]
Dexfenfluramine	DMJ7YDS	Major	Additive serotonergic effects by the combination of Sertraline and Dexfenfluramine.	Obesity [5B80-5B81]	[87]
Polythiazide	DMCH80F	Moderate	Increased risk of hyponatremia by the combination of Sertraline and Polythiazide.	Oedema [MG29]	[130]
Urea	DMUK75B	Moderate	Increased risk of hyponatremia by the combination of Sertraline and Urea.	Oesophagitis [DA24]	[130]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Sertraline and Levomethadyl Acetate.	Opioid use disorder [6C43]	[95]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and Lofexidine.	Opioid use disorder [6C43]	[94]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and Rucaparib.	Ovarian cancer [2C73]	[94]
Oxymorphone	DM65AGJ	Moderate	Additive serotonergic effects by the combination of Sertraline and Oxymorphone.	Pain [MG30-MG3Z]	[96]
Dezocine	DMJDB0Y	Moderate	Additive serotonergic effects by the combination of Sertraline and Dezocine.	Pain [MG30-MG3Z]	[96]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and Triclabendazole.	Parasitic worm infestation [1F90]	[94]
Safinamide	DM0YWJC	Moderate	Additive serotonergic effects by the combination of Sertraline and Safinamide.	Parkinsonism [8A00]	[127]
Rasagiline	DM3WKQ4	Major	Additive serotonergic effects by the combination of Sertraline and Rasagiline.	Parkinsonism [8A00]	[88]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and Pimavanserin.	Parkinsonism [8A00]	[131]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Sertraline caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[132]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Sertraline and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[133]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Sertraline and Lefamulin.	Pneumonia [CA40]	[134]
Choline salicylate	DM8P137	Moderate	Increased risk of bleeding by the combination of Sertraline and Choline salicylate.	Postoperative inflammation [1A00-CA43]	[97]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and Degarelix.	Prostate cancer [2C82]	[95]
ABIRATERONE	DM8V75C	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and ABIRATERONE.	Prostate cancer [2C82]	[95]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and Enzalutamide.	Prostate cancer [2C82]	[95]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and Relugolix.	Prostate cancer [2C82]	[95]
Levomepromazine	DMIKFEL	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and Levomepromazine.	Psychotic disorder [6A20-6A25]	[94]
Epoprostenol	DMUTYR2	Moderate	Increased risk of bleeding by the combination of Sertraline and Epoprostenol.	Pulmonary hypertension [BB01]	[97]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Sertraline and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[135]
Aripiprazole	DM3NUMH	Moderate	Decreased metabolism of Sertraline caused by Aripiprazole mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[112]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Sertraline and Iloperidone.	Schizophrenia [6A20]	[94]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and Paliperidone.	Schizophrenia [6A20]	[94]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Sertraline and Amisulpride.	Schizophrenia [6A20]	[136]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and Asenapine.	Schizophrenia [6A20]	[94]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Sertraline caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[95]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Sertraline caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[112]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Sertraline and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[94]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Sertraline and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[94]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[95]
Pitolisant	DM8RFNJ	Moderate	Decreased metabolism of Sertraline caused by Pitolisant mediated inhibition of CYP450 enzyme.	Somnolence [MG42]	[95]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[94]
Plicamycin	DM7C8YV	Moderate	Increased risk of bleeding by the combination of Sertraline and Plicamycin.	Testicular cancer [2C80]	[97]
Fostamatinib	DM6AUHV	Moderate	Decreased clearance of Sertraline due to the transporter inhibition by Fostamatinib.	Thrombocytopenia [3B64]	[137]
Caplacizumab	DMPUKA7	Moderate	Increased risk of bleeding by the combination of Sertraline and Caplacizumab.	Thrombocytopenia [3B64]	[97]
Apixaban	DM89JLN	Moderate	Increased risk of bleeding by the combination of Sertraline and Apixaban.	Thrombosis [DB61-GB90]	[97]
Cangrelor	DM8JRH0	Moderate	Increased risk of bleeding by the combination of Sertraline and Cangrelor.	Thrombosis [DB61-GB90]	[97]
Brilinta	DMBR01X	Moderate	Increased risk of bleeding by the combination of Sertraline and Brilinta.	Thrombosis [DB61-GB90]	[97]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Sertraline and Lenvatinib.	Thyroid cancer [2D10]	[94]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Sertraline and Cabozantinib.	Thyroid cancer [2D10]	[95]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Sertraline and Papaverine.	Tonus and reflex abnormality [MB47]	[138]
Tolbutamide	DM02AWV	Moderate	Increased risk of hypoglycemia by the combination of Sertraline and Tolbutamide.	Type 2 diabetes mellitus [5A11]	[91]
Insulin-detemir	DMOA4VW	Moderate	Increased risk of hypoglycemia by the combination of Sertraline and Insulin-detemir.	Type-1/2 diabete [5A10-5A11]	[91]
Insulin degludec	DMPL395	Moderate	Increased risk of hypoglycemia by the combination of Sertraline and Insulin degludec.	Type-1/2 diabete [5A10-5A11]	[91]
Betrixaban	DM2C4RF	Moderate	Increased risk of bleeding by the combination of Sertraline and Betrixaban.	Venous thromboembolism [BD72]	[97]
Propafenone	DMPIBJK	Moderate	Decreased metabolism of Sertraline caused by Propafenone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[139]
Flecainide	DMSQDLE	Moderate	Decreased metabolism of Sertraline caused by Flecainide mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[139]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Sertraline and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[94]
-----------


⏷ Show the Full List of 155 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
Butylated hydroxytoluene	E00336	31404	Antioxidant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Food blue 1 aluminum lake	E00512	11979396	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite	E00392	104805	Diluent
Calcium hydrogenphosphate	E00294	24441	Diluent
Carmellose sodium	E00625	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Glycerin	E00026	753	Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Hydroxypropyl cellulose	E00632	Not Available	Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 3350	E00652	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000	E00655	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent
--------------------


⏷ Show the Full List of 32 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Sertraline 100 mg tablet	100 mg	Oral Tablet	Oral
Sertraline 25 mg tablet	25 mg	Oral Tablet	Oral
Sertraline 50 mg tablet	50 mg	Oral Tablet	Oral
Sertraline Hydrochloride eq 50mg base tablet	eq 50mg base	Tablet	Oral
Sertraline Hydrochloride eq 25mg base tablet	eq 25mg base	Tablet	Oral
Sertraline 150 mg tablet	150 mg	Oral Tablet	Oral
Sertraline 200 mg tablet	200 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4798).
2	Emerging treatments for depression. Expert Opin Pharmacother. 2006 Dec;7(17):2323-39.
3	Clinical pharmacokinetics of sertraline. Clin Pharmacokinet. 2002;41(15):1247-66. doi: 10.2165/00003088-200241150-00002.
4	BDDCS applied to over 900 drugs
5	Murdoch D, McTavish D: Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder. Drugs. 1992 Oct;44(4):604-24.
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6.
8	Methadone: from pharmacokinetic profile to clinical pharmacology. Encephale. 2006 Jul-Aug;32(4 Pt 1):478-86.
9	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
10	New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients. Ther Clin Risk Manag. 2014 Jun 13;10:423-36.
11	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA166181117)
12	Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie. 2004 Jan-Feb;59(1):5-12.
13	Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2005 Feb;33(2):262-70.
14	Influence of CYP2B6 and CYP2C19 polymorphisms on sertraline metabolism in major depression patients. Int J Clin Pharm. 2016 Apr;38(2):388-94.
15	The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders. CNS Drug Rev. 2001 Spring;7(1):1-24.
16	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
17	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
18	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
19	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
20	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
21	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
22	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
23	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
24	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
25	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
26	Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
27	Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
28	Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
29	PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
30	The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
31	The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
32	Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
33	Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
34	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
35	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
36	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
37	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
38	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
39	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
40	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
41	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
42	Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
43	Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
44	Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
45	Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
46	A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
47	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
48	Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
49	Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
50	CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
51	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
52	Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
53	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
54	Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
55	Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
56	New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
57	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
58	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
59	Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
60	Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
61	Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
62	Drugs that may have potential CYP2B6 interactions.
63	Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
64	Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
65	PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
66	Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
67	High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
68	Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
69	CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
70	Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
71	Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
72	Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
73	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
74	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
75	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
76	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
77	Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
78	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
79	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
80	Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
81	Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
82	Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
83	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
84	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
85	Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
86	Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
87	Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
88	Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL "Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings." J Clin Psychopharmacol 13 (1993): 312-20. [PMID: 8227489]
89	Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6. [PMID: 9562139]
90	Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
91	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
92	Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
93	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
94	Canadian Pharmacists Association.
95	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
96	Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
97	Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
98	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
99	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
100	Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
101	Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
102	Lee DO, Lee CD "Serotonin syndrome in a child associated with erythromycin and sertraline." Pharmacotherapy 19 (1999): 894-6. [PMID: 10417041]
103	Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90. [PMID: 18584781]
104	Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
105	Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6. [PMID: 2530759]
106	Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
107	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
108	Cerner Multum, Inc. "Canadian Product Information.".
109	Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
110	Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
111	Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
112	Cerner Multum, Inc. "Australian Product Information.".
113	Auclair B, Berning SE, Huitt GA, Peloquin CP "Potential interaction between itraconazole and clarithromycin." Pharmacotherapy 19 (1999): 1439-44. [PMID: 10600094]
114	Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM "Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe." J Clin Pharmacol 41 (2001): 443-51. [PMID: 11304901]
115	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
116	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
117	Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
118	Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
119	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
120	Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
121	Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
122	Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
123	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
124	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
125	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
126	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
127	Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
128	Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
129	Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
130	Product Information. Savella (milnacipran). Forest Pharmaceuticals, St. Louis, MO.
131	Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
132	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
133	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
134	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
135	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
136	Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
137	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
138	Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
139	Alfaro CL, Lam YWF, Simpson J, Ereshefsky L "CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline." J Clin Psychopharmacol 19 (1999): 155-63. [PMID: 10211917]